期刊
PAIN
卷 157, 期 11, 页码 2493-2503出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/j.pain.0000000000000668
关键词
Fibromyalgia syndrome; MicroRNA; miR; Microarray; Skin biopsy; miRNAlet-7d; IGF-1R
资金
- Research Training Group Emotions (German Research Foundation, DFG) of the Graduate School of the University of Wurzburg, Germany [RTG 1253/1]
- Kedrion
- Astellas
- Baxalta
- CSL Behring
- Genzyme
- Pfizer Inc
- Genzyme Corp
- Shire Corp
- Grunenthal GmbH
- European Union's Seventh Framework Programme [602133]
- Genzyme Corp. C. Sommer
Fibromyalgia syndrome (FMS) is a chronic widespread pain condition probably comprising subgroups with different underlying pathomechanisms. There is increasing evidence for small nerve fiber impairment in subgroups of patients with FMS. MicroRNAs (miRNAs) regulate molecular factors determining nerve de-and re-generation. We investigated whether systemic and cutaneous miRNA expression in patients with FMS is related to small nerve fiber pathology. We confirmed previous findings of disturbed small fiber function and reduced intraepidermal nerve fiber density in subgroups of patients with FMS. We found 51 aberrantly expressed miRNAs in white blood cells of patients with FMS, of which miR-let-7d correlated with reduced small nerve fiber density in patients with FMS. Furthermore, we demonstrated miR-let-7d and its downstream target insulin-like growth factor-1 receptor as being aberrantly expressed in skin of patients with FMS with small nerve fiber impairment. Our study gives further evidence of small nerve fiber pathology in FMS subgroups and provides a missing link in the pathomechanism that may lead to small fiber loss in subgroups of patients with FMS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据